Soft tissue sarcomas represent a heterogeneous group of rare malignancies exhibiting mesenchymal differentiation with an overall incidence of around 5/100,000/year. Rarity and morphologic heterogeneity significantly affect diagnostic accuracy; therefore, expertise can be achieved only through access to large number of cases. Soft tissue sarcomas are currently classified on the basis of the 2013 WHO classification of soft tissue tumors that integrate conventional morphology with immunohistochemistry and molecular genetics. The morphologic diagnosis of sarcoma relies on the evaluation as well as the integration of four main features: the shape of the neoplastic cells; the pattern of growth; the quality of the background; the architecture of the vascular network. Immunohistochemical characterization plays a key role in the diagnostic workup of soft tissue sarcomas. The majority of classic differentiation markers tend to show good sensitivity, however, associated with rather limited specificity, making interpretation in context with morphology mandatory. Molecular genetics is increasingly used for diagnostic purposes to distinguish specific subtypes of sarcomas, to support diagnosis in non-canonical clinical presentations and also to distinguish true sarcomas from benign mimickers. With many exceptions, histologic typing does not provide sufficient information for predicting the clinical course of the disease and, therefore, grading systems based on histological parameters were introduced to provide a more accurate estimation of the degree of malignancy of tumors. The three-tiered system devised by the French Federation of Cancer Centers Sarcoma Group (FNCLCC) systems is widely adopted; however, several limitations exist that have led to the development of prognostic nomograms that incorporate the specific histotype as one of the relevant parameters.
Introduction
Soft tissue sarcomas represent a heterogeneous group of rare malignancies with an overall incidence of around 5/100,000/ year. Half of the cases occur in the limbs (wherein the thigh is by far the commonest site), 30% occur intra-abdominally (including the retroperitoneum), and 15% arise in the trunk and in the head and neck region. Both incidence and site of occurrence tend to correlate with the specific histotypes. For example, whereas myxoid liposarcoma arises predominantly in the thigh of young adults, myxofibrosarcoma most often occurs in the superficial soft tissues of elderly patients.
Soft tissue sarcomas are aggressive neoplasm capable of local destructive growth, recurrence and distant metastases, most often to lungs, liver, bone, soft tissue and brain. Lymph node metastases are comparatively more rare. Fiveyear overall survival varies between 55 and 65%, regardless of stage and histology.
Mesenchymal tumors have always been regarded as diagnostically challenging. In fact rarity and morphologic heterogeneity significantly affect diagnostic accuracy [1] . As a consequence, expertise can be achieved only through access to large number of cases. To avoid major mistakes, careful evaluation of clinical presentation and integration of immunohistochemistry and molecular genetics whenever relevant are mandatory.
Soft tissue sarcomas are currently classified on the basis of the 2013 WHO classification of soft tissue tumors [2] . WHO classifies the different entities on the basis of histomorphology and includes all available immunophenotypic and genetic data since the 2002 edition [3] . This perfectly matches a diagnostic approach that integrates sequentially the microscopic features of the lesion with its immunophenotype and its genetic profile. Soft tissue sarcomas and soft tissue tumors of intermediate malignancy currently recognized by WHO classification are listed in Table 1 . The major advances introduced since 2002 can be summarized as follows:
Adipocytic tumors
One of the major changes introduced since 2002 is represented by the use of a stricter terminological definition of well-differentiated liposarcoma, which represents the commonest of liposarcoma subtypes. It has been clarified that the terms "atypical lipomatous tumor" and "well-differentiated liposarcoma" are synonyms and that the latter term should only be used for lesions that occur in the retroperitoneum/mediastinum or in other anatomic sites where complete resectability is unachievable. The use of the term "atypical lipomatous tumors" for resectable lesions is justified by the fact they never recur and are most often cured by complete (even marginal) surgical excision. In 2002, it was recognized that in "dedifferentiated liposarcoma" (defined as morphological progression from well-differentiated liposarcoma to high-grade non-lipogenic sarcoma), also a low-grade dedifferentiation can be observed. In 2013, the concept of homologous dedifferentiation (represented by the occurrence of lipogenic high-grade morphology somewhat mimicking pleomorphic liposarcoma) was fully acknowledged. A major change also involved "myxoid liposarcoma" that until 2002 was kept separated from "round cell liposarcoma". To reflect the fact that both lesions actually represent the ends of a morphological spectrum of a genetically distinct histology, in 2002 myxoid and round cell liposarcoma merged in one single entity. In 2013, the term "round cell liposarcoma" was eliminated and replaced by the label "high-grade myxoid liposarcoma" to underline the fact that clinical outcome depends on the amount of hypercellularity and not on the shape on neoplastic cells that can be either rounded or spindled.
Fibroblastic/myofibroblastic tumors
A key conceptual change was represented by the inclusion of "hemangiopericytoma" (HPC) since 2002 within the chapter on solitary fibrous tumor. At that time, it was already clear that HPC merely represented a collection of unrelated, benign as well as malignant, sharing an HPC-like vascular network (i.e., the presence of dilated, thin-walled, branched blood vessels) Fig. 1 . As a logical consequence of this conceptual evolution in 2013, the label hemangiopericytoma (HPC) has been completely abolished. Currently, the original (still valid) idea generated by Arthur Purdy Stout of the existence of lesions mainly composed of contractile cells organized in a perivascular pattern of growth survives within the label "myopericytoma". "Fibrosarcoma" also experienced a significant remodeling. Whereas it is currently recognized that most superficially located fibrosarcomas actually represent examples of "fibrosarcomatous dermatofibrosarcoma protuberans" (FS-DFSP), "Infantile fibrosarcoma" is confirmed as a clinically, pathologically and, genetically distinct entity. However, new distinctive sarcoma subtypes featuring fibroblastic/ myofibroblastic differentiation has been introduced. These are "low-grade fibromyxoid sarcoma", "myxoinflammatory fibroblastic sarcoma", "sclerosing epithelioid fibrosarcoma", and "low-grade myofibroblastic sarcoma".
So-called fibrohistiocytic tumors
The same destiny of HPC occurred to "malignant fibrous histiocytoma" (MFH) who also totally disappeared in 2013. One of the major steps was first the reappraisal of malignant fibrous histiocytoma (MFH) and its variants and now its complete abolition. As of today "pleomorphic MFH", once the most commonly diagnosed sarcoma, is now synonymous with high-grade undifferentiated pleomorphic sarcoma and it should not exceed approximately 5% of newly diagnosed sarcomas. "Myxoid MFH" is now included within the morphologic spectrum of myxofibrosarcoma. The so-called "giant cell variant of MFH" appears to be an heterogeneous collection of clinically as well as morphologically distinctive lesions that includes giant cell tumor of soft tissue, extraskeletal osteosarcoma, and spindle cell sarcoma (most often leiomyosarcoma) featuring osteoclast-like giant cells. The "inflammatory variant of MFH" most often represents examples of inflammatory dedifferentiated liposarcoma. "Angiomatoid MFH", the latest addition to the MFH family, is no longer considered a malignancy and has, therefore, been downgraded to the intermediate category. As its line of differentiation remains unknown, it has also been moved to the category of mesenchymal tumors of uncertain differentiation.
The existence of a broader category of "undifferentiated sarcomas" (pleomorphic, epithelioid, round cell, and spindle cell) is now fully acknowledged. In the heading of undifferentiated round cell sarcomas are temporarily classified those round cell sarcomas harboring the CIC-DUX4 or the BCOR-CCNB3 translocations.
Vascular tumors
In the last two decades, several new entities have been characterized, particularly in the intermediate malignancy category, including the "kaposiform", "retiform", and "composite hemangioendothelioma". Since the 2002 WHO classification "Epithelioid hemangioendothelioma" (EHE) 
Tumors of uncertain differentiation
This category contains tumors without a clear line of differentiation or without a normal cellular counterpart. Obviously, several new entities have been described including "myoepithelioma of soft tissue" and "PEComa". Since we now know more about divergent differentiation in various sarcomas subtypes, the category of "malignant mesenchymoma" is also losing ground as it is currently acknowledged that heterologous differentiation may occur in context of specific entities such as malignant peripheral nerve sheath tumor (MPNST) and dedifferentiated liposarcoma. The morphologically rather elusive category of "intimal sarcoma" was introduced as a new entity in this group.
Principles of sarcomagenesis
The pathogenesis of the vast majority of soft tissue sarcomas is still unknown and most of them arise de novo without an apparent causative factor. In rare cases, genetic and environmental factors such as radiation, lymphedema (secondary angiosarcoma of the breast), viral infections (HHV8 infection is associated with Kaposi Sarcoma), exposure to chemicals (vinyl chloride is linked to hepatic angiosarcoma), and immunodeficiency (EBV infection in immunodeficient subjects is associated with the development of smooth muscle tumors) have been identified as risk factors. It is broadly accepted that trauma does not represent a predisposing factor and that, at best, it can simply draw attention to the presence of pre-existing mass. Genetic susceptibility plays a role in a minority of soft tissue sarcomas. Neurofibromatosis type 1 (NF1) and Li-Fraumeni syndromes represent two good examples. In NF1, up to 10% of patients will develop MPNST as well as multiple GIST. The autosomal dominant Li-Fraumeni syndrome (wherein germline mutations of the TP53 gene occur) has been shown to predispose to the development of malignant tumors, one-third of which are represented by bone and soft tissue sarcomas. Recent data have shown that approximately half of patients with sarcoma have putatively pathogenic monogenic and polygenic variation in known and novel cancer genes among which are TP53, ATM, ATR , BRCA2, and ERCC2 [4] .
In the last two decades, molecular genetics have greatly contributed to elucidate some of the molecular mechanisms associated with the development of soft tissue sarcomas [5] [6] [7] . Significant subsets of mesenchymal malignancies are associated with chromosome translocations, the presence of which is currently being exploited for diagnostic confirmation (Table 2) . A smaller group of lesions are characterized by the presence of simple karyotypes associated with mutations. Good examples are represented by desmoid fibromatosis (the vast majority of which are associated with mutations of either the CTNNB1 or APC genes) and gastrointestinal stromal tumors (most often associated with mutation of the KIT and PDGFRA genes and far less often of the BRAF, SDH and NF1 genes). A third (large) group of sarcomas exhibits variably complex karyotypes. In this context, particularly relevant is the occurrence of gene copy number alterations as observed in well-differentiated/dedifferentiated liposarcoma, wherein the amplification of the MDM2, CDK4 and HMGA2 genes represents the key driver genetic event.
Pathologic diagnosis
Sarcomas are currently classified on the basis of their morphology, their immunophenotype, and their molecular status. The integration of conventional morphology with immunohistochemistry and molecular genetics represents the major contribution of WHO classification since 2002 and this approach has been further confirmed in 2013. For practical reasons, the classification scheme follows a histogenetic approach, even though currently it is no longer believed that a given mesenchymal neoplasm actually originates from a mature normal counterpart. Interestingly, the list of lesions of unknown histogenesis (i.e., unknown line of differentiation) has increased in size, reflecting the uncertainties surrounding the mechanisms of sarcomagenesis.
Microscopic observation of hematoxylin-and eosinstained slides still represents the mainstay of sarcoma classification. The amount of information provided by this technically simple step is invaluable. Any other ancillary technique (immunohistochemistry and/or molecular pathology/genetics), even the most sophisticated, certainly represents an important complement to, but under no circumstances a replacement for, classic morphological observation. It should be also noted that macroscopic observation too plays a fundamental role, firstly in providing accurate reporting of the status of surgical margins, and secondly in guiding proper sampling and, therefore, posing the milestone for correct classification. It is also possible that in the near future, similarly to what already happens for osteosarcoma and Ewing sarcoma, the morphologic evaluation of tumor response to systemic treatment will gain significant clinical relevance. t(9;X)(p24;p11) t(9;12)(q34;q23) t(2;6)(q12;p21) Tenosynovial giant cell tumor COL6A3-CSF1 t(1;2)(p13;q37) Pericytoma with t(7;12)t(7;12) ACTB-GLI1 t(7;12)(p22;q13) Alveolar rhabdomyosarcoma
t(2;13)(Q35;Q14) t(1;13)(p36;q14) t(X;2)(q13;q36) t(2;2)(p23;q36) t(2;8)(q36;q13) t(8;13;9)(p11;q14;q32) Spindle cell rhabdomyosarcoma SRF-NCOA2 TEAD1-NCOA2 
Microscopic examination of soft tissue sarcomas
Despite the intrinsic challenge of sarcoma diagnosis, is possible to achieve a correct classification in most instances, provided that cases are approached following a rigorous methodology. The diagnosis of sarcoma relies upon the evaluation as well as the integration of four main features:
1. The predominant shape of the neoplastic cells.
2. The pattern of growth. 3. The quality of the background. 4. The architecture of the vascular network.
This approach possesses the great merit of reducing dramatically the number of diagnostic options, also allowing a rational choice of ancillary immunohistochemical and molecular tests. Of course this approach needs some degree of flexibility as numerous entities may at times exhibit a combination of different major morphologic features.
The shape of neoplastic cells
Neoplastic cells can be classified on the basis of their shapes into four main categories: spindle, epithelioid, round and pleomorphic.
1. Spindle cells are defined by the presence of an elongated cytoplasm, harboring oval nuclei that can be blunt-ended (as typically seen in smooth muscle tumors) (Fig. 2a) , tapering (as seen in myofibroblastic tumors) or pointed (as seen most often in neural neoplasm). Soft tissue malignancies featuring a predominantly spindle cell morphology are listed in Table 3 . 2. Epithelioid cells are defined by the presence of polygonal, abundant cytoplasm, most often harboring a round shaped nucleus (Fig. 2b) . Soft tissue malignancies featuring predominantly epithelioid cell morphology are listed in Table 4 . 3. Round cells are defined by the presence of circular scanty cytoplasm, harboring centrally located round nuclei (Fig. 2c) . Soft tissue malignancies featuring predominantly round cell morphology are listed in Table 5 . 4. Pleomorphic cells are defined on the basis of marked nuclear atypia represented by extreme variation of nuclear size with or without macronucleolation, and nuclear hyperchromasia (Fig. 2d) . Soft tissue malignancies featuring a predominantly pleomorphic morphology are listed in Table 6 .
The patterns of growth
The pattern of growth of the neoplastic cell population is extremely important as helps to further refine the possible diagnostic options. The main patterns are as follows: 
The quality of the background
The quality of the background refers to the characteristics of the extracellular stroma in which the neoplastic cell population is embedded. (Table 7 ). 4. Myxochondroid: neoplastic cells are set in a stroma rich of mucin. In addition, the stroma assumes a more condensed texture, somewhat similar to the chondrogenic matrix. This type of stroma can be observed in epithelioid hemangioendothelioma. 5. Osteogenic: neoplastic cells are surrounded by dense eosinophilic matrix most often organized in a lace-like configuration. The presence of osteogenic matrix represents prerequisite to the diagnosis of extraskeletal osteosarcoma.
The architecture of the vascular network
Blood vessels can variably organize to form a plexiform, archiform, and HPC-like architecture. These features can be extremely helpful in recognizing specific tumor entities at least to address the differential diagnosis within a limited number of options.
1. Plexiform architecture: blood vessels are capillary size and organized to form a richly anastomosed network.
This patter has been variably labeled as "chicken wire" of "crow's feet" depending on the imagination of the pathologist. This architecture is typically observed in myxoid liposarcoma (Fig. 3a) . 2. Archiform architecture: blood vessels are capillary size and exhibit an archiform shape. This architecture is typically observed in myxofibrosarcoma (Fig. 3b ). 3. Hemangiopericytoma-like architecture: blood vessels are branching, dilated, thin-walled generating a "staghorn" configuration. This architecture is observed in several (from benign to malignant) tumor entities but most often in solitary fibrous tumor and synovial sarcoma (Fig. 1) . The lesions associated with an HPC-like vascular network are listed in Table 8 .
As already mentioned, the integration of the abovementioned morphologic features which is enable to reduce significantly the number of diagnostic options to the extent that in some instances ancillary technique may play a rather limited role. However, in many situations an accurate diagnosis may require a second step represented by application of a variable (ideally relatively limited) number of immunohistochemical stains.
Immunohistochemical characterization of soft tissue tumors
Immunohistochemical characterization plays a key role in the diagnostic workup of soft tissue sarcomas [8, 9] . However, a blind application of a broad range of immunophenotypic markers unsupervised by morphology most often leads to diagnostic errors. The number of potential diagnostic markers has grown exponentially through the years; however in consideration of the natural evolution of the field, some markers have lost their role while others have gained diagnostic relevance. It has to be underlined that, with some exceptions that will be discussed, the majority of classic differentiation markers tend to show good sensitivity, however, associated with rather limited specificity. This may not represent a problem only if interpretation is strictly handled in context with morphology. We will herein focus upon those differentiation markers showing major diagnostic as well as clinical relevance. The use of panel of immunostains driven by morphology is felt to represent the most efficient approach.
Myogenic differentiation markers
Classic myogenic markers are basically represented by smooth muscle actin, muscle specific actin, desmin, and h-caldesmon.
Demonstration of myogenic (both smooth muscle and striated) differentiation is clinically relevant in the following situations:
1. To recognize adult myogenic sarcomas in general. 2. To differentiate between rhabdomyosarcoma and nonrhabdomyosarcoma pediatric soft tissue tumors (those two broad groups definitely undergo distinct systemic treatments).
3. To identify rhabdomyoblastic differentiation in malignant peripheral nerve sheath tumors. 4. To identify myogenic differentiation in dedifferentiated liposarcoma.
Smooth muscle actin immunopositivity is observed in most smooth muscle tumors but also, in myofibroblastic, myoepithelial and pericytic neoplasm. Muscle specific actin (HHF-35) also stains smooth muscle lesions and, however, also represents a very sensitive markers of striated muscle differentiation, staining up to 90% of rhabdomyosarcomas of all subtypes (embryonal, alveolar, and pleomorphic). Desmin belongs to the category of intermediate filaments and represents a valid marker for both smooth muscle and striated muscle lineage. H-caldesmon immunoreactivity is observed in most smooth muscle neoplasm. In contrast with other smooth muscle markers, it tends to be negative in myofibroblastic lesions as well as in rhabdomyoblastic neoplasm.
The most specific and sensitive markers to demonstrate rhabdomyoblastic differentiation remain myogenin (MYF4), a lineage restricted nuclear transcription factor involved in striated muscle differentiation. Recently, it has been shown that MyoD1 (MYF3), an alternative nuclear transcription factor involved with the development of striated muscle, represents the most sensitive marker for the spindle cell variant of rhabdomyosarcoma, wherein MyoD1 gene homozygous mutations have shown to occur.
Neural differentiation markers
Paradoxically, the best use of the prototypic schwannian differentiation markers, namely S100 protein, is achieved out of context of recognition of MPNST. In fact, approximately only 30% of malignant peripheral nerve sheath tumors (MPNST) exhibit S-100 positivity, which is usually limited to less than 30% of neoplastic cells. Epithelioid MPNST represents an important exception as S-100 usually decorates most neoplastic cells. It has to be stressed that S100 exhibits a distinctive multispecificity to the extent that its evaluation needs to be strictly performed in context with morphology. The best use of S100 immunostains is as follows:
1. Recognition of benign neural neoplasm. 2. Support in the diagnosis of cellular schwannoma (that in contrasts with MPNST) express S100 diffusely. Another member of the group of the intermediate filaments, glial fibrillary acidic protein (GFAP) is also detectable in Schwann cells. When dealing with soft tissue neoplasm, it may stain a minority of MPNST; however, its sensitivity does not exceed that of S100. GFAP immunopositivity can also be observed in myoepithelial neoplasm. SOX10 and H3K27me3 (histone 3K27 trimethylation) represent more recently introduced markers that can be used in the diagnosis of neural soft tissue neoplasm. SOX10 is involved in melanogenesis and schwannian differentiation, and has been proposed as a valid immunohistochemical marker for both melanocytic and neural neoplasm. SOX10 tends to immunostain the vast majority of benign neural mesenchymal lesion whereas when dealing with MPNST its sensitivity is much lower, with approximately 20% of cases showing positivity in a minority of neoplastic cells. H3K27me expression tends to be lost in approximately half of MPNST as a consequence of homozygous inactivation of the polycomb repressive complex 2 (PRC2).
Epithelial differentiation markers
Any soft tissue neoplasm featuring true epithelial differentiation or epithelioid morphology is characterized by variable expression of epithelial differentiation markers, namely cytokeratin and epithelial membrane antigen (EMA). Cytokeratin expression is observed in up to 80% of classic synovial sarcomas and in about half of the poorly differentiated ones. Cytokeratin AE1/AE3 decorates virtually all examples of epithelioid sarcomas, desmoplastic small round cell tumor and pseudomyogenic hemangioendothelioma. Epithelial membrane antigen also stains most epithelioid sarcomas, and 90% of synovial sarcoma (including poorly differentiated ones), therefore, representing the most sensitive marker of epithelial differentiation in this context.
Endothelial differentiation markers
Demonstration of endothelial differentiation appears crucial when dealing with poorly differentiated vascular neoplasms, in particular epithelioid angiosarcoma that may often lacks overt vasoformative morphology. CD34, CD31, and Fli1 represent time-honored but still valid markers. When dealing with vascular neoplasm CD34 is very sensitive, but it has to be stressed that is also expressed in half of epithelioid sarcomas in addition to an endless list of non-vascular spindle cell neoplasms. Much more specific as well as extremely sensitive is the transmembrane glycoprotein CD31. ERG represents a recently developed, sensitive, endothelial marker. In the recent years, as a byproduct of new insights in the molecular pathogenesis of vascular neoplasm, a number of new diagnostic immunohistochemical markers have been made available. The recognition of EHE is currently greatly helped by the detection of nuclear expression of CAMTA1 that is observed in those cases harboring a WWTR1-CAMTA1 gene fusion. TFE3 nuclear expression is observed in a subset of EHE carrying the YAP1-TFE3 gene fusion. FOSB expression is consistently observed in pseudomyogenic hemangioendothelioma (associated with an FOSB-SERPIN1 gene fusion) as well as in subset of epithelioid hemangioma.
Melanocytic differentiation markers
Despite total lack of specificity S100 remains the most sensitive marker of melanocytic differentiation. HMB-45, Melan-A (MART1) and MITF1 all represent sensitive melanocytic differentiation; however, their sensitivity drops significantly when dealing with sarcomatoid variants of malignant melanoma, wherein S100 is most often the only expressed diagnostic marker. S100 negativity in "bona fide" examples of metastatic melanoma may occur but it represents a much more rare event. They not only play an obvious role in the differential diagnosis of malignant melanoma, but they have also proved extremely helpful in recognizing the members of the clinically as well as morphologically heterogeneous family of PEComas, as well in the proper classification of clear cell sarcoma.
Other useful immunohistochemical markers
There exist an increasing number of immunohistochemical markers that despite variable specificity play a major role in the differential diagnosis of soft tissue sarcomas.
ALK (anaplastic lymphoma kinase)
Cytoplasmic expression of the tyrosine kinase ALK plays a key role in supporting the diagnosis of inflammatory myofibroblastic tumor (IMT), including the aggressive epithelioid subtypes. Unfortunately, approximately half of cases of IMT lack ALK expression.
Beta-catenin Nuclear expression of beta-catenin represents an extremely valuable confirmatory finding in the diagnosis of desmoid fibromatosis. Nuclear accumulation is due to mutation of the CTNNB1 gene (found in up to 90% of sporadic desmoid fibromatosis) or alternatively, of the APC gene (in the context of Gardner's Syndrome).
Brachyury (T)
Nuclear expression of brachyury represents a key diagnostic feature in the recognition of chordoma and is very helpful in the differential diagnosis with chondrosarcoma, metastatic carcinoma and myoepithelial neoplasms.
CD99
When dealing with the differential diagnosis of small round cell sarcomas, CD99 (a cell surface glycoprotein normally expressed on thymic T cells) represents a powerful diagnostic marker. In fact virtually all Ewing's sarcomas exhibit strong CD99 immunopositivity, to the extent that such a diagnosis should be regarded as doubtful in case of CD99 negativity. However, it has to be underlined that CD99 is expressed rather broadly. Importantly, immunopositivity in non-Ewing tumors tends to be more diffuse, rarely matching the thick membrane staining typically observed in Ewing sarcoma.
Cyclin-B3 Expression of the cell cycle regulator Cyclin-B3 seems to be useful in the recognition of a small subset or poorly differentiated round cell sarcomas associated with a BBCOR-CNNB3 gene fusion. DOG1 (discovered on GIST 1) DOG1 represents a useful and sensitive marker for diagnosis of GIST and is extremely helpful in rescuing at least half of KIT-negative GIST cases.
INI1 (SMARCB1)
INI1 also known as SMARCB1 is a member of the BAF molecular complex that contributes to the process of chromatin remodeling and plays a key role in regulating transcription of DNA. Loss of INI1 nuclear expression is consistently observed in malignant rhabdoid tumors (including atypical teratoid rhabdoid tumors of CNS) as a consequence of INI1 biallelic inactivation. Loss of INI1 is also observed in up to 95% of both classic and proximal variants of epithelioid sarcoma wherein it tends to be associated with homozygous deletion of the INI1 locus. INI1 negativity has been described also in up to 70% of epithelioid MPNST, in 10-35% of myoepithelial carcinoma, and in almost all renal medullary carcinoma.
KIT (CD117)
KIT represents a tyrosine kinase receptor that is involved on the development of mast cells, melanocytes and interstitial cells of Cajal. KIT has become one of the most clinically relevant phenotypic markers. In fact its expression in GIST permits the accurate recognition of this once orphan tumor, offering proper selection of patients for treatment with tyrosine kinase inhibitors. KIT expression does not predict response to tyrosine kinase inhibitors and can be observed in unrelated neoplasm such as seminoma, thymic carcinoma, melanocytic neoplasm, and mast cell disorders.
MDM2 (murine double minutes)
MDM2 is the product of the MDM2 proto-oncogene, the main function of which is to promote cell proliferation via inhibition of TP53. Both well-differentiated liposarcoma and dedifferentiated liposarcoma are characterized by strong nuclear overexpression of MDM2 as a consequence of MDM2 gene amplification. MDM2 overexpression related to gene amplification is also observed in intimal sarcoma and in bone by low-grade osteosarcoma.
MUC4 (Mucin 4)
MUC4 is a high molecular weight transmembrane glycoprotein normally expressed in epithelial cells. The major diagnostic role of MUC4 is represented by diagnostic confirmation of both low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, wherein gene expression profiling has identified its upregulation.
RB (retinoblastoma gene product)
RB is the product of the RB tumor suppressor gene that acts as a potent negative regulator of cell cycle. From the diagnostic standpoint, loss of nuclear expression of RB is observed in spindle cell and pleomorphic lipoma. The same phenomenon is observed also in atypical spindle cell lipomatous tumor.
SATB2
Nuclear expression of SATB2 (special AT-rich sequence-binding protein 2) is observed in neoplasm featuring osteogenic differentiation. Normal function of SATB2 is to enable osteoblast lineage commitment. Importantly, SATB2 expression is shared by both normal and neoplastic osteoblast and, therefore, plays no role in the differential diagnosis between benign and malignant osteogenic neoplasms. SATB2 is best used whenever H&E does not discriminate unequivocally between osteoid and sclerotic collagen, or when osteoid is minimally or not represented in the sample.
STAT6
Nuclear expression of STAT6 is consistently expressed in all variant of solitary fibrous tumors as a consequence of the NAB2-STAT6 gene fusion.
TFE3 TFE3 decorates the neoplastic cell population of alveolar soft part sarcoma (as a consequence, the presence of the ASPSCR1-TFE3 gene fusion leads to the overexpression of the TFE3 protein), but as other markers it is not entirely specific. In fact, it is expressed also in Xp11 translocated renal cell carcinomas, in a small subset (approximately 5%) of perivascular epithelioid cell tumors (PEComa), and in a small subset of epithelioid hemangioendothelioma.
TLE1 TLE1 is a transcriptional co-repressor that inhibits WNT signaling. Gene profiling studies have demonstrated high levels of TLE1 in synovial sarcoma that can be detected immunohistochemically.
WT1
Nuclear expression of the c-terminus WT1 (Wilms tumor 1) can be used as a confirmatory tool in the diagnosis of desmoplastic small round cell tumor.
The demonstration by FISH of EWSR1, SS18 and FOXO1 rearrangements in Ewing sarcoma, RMS and PDSS, respectively, or, alternatively, of specific chimerical transcripts by PCR-based techniques or via an NGS-based approach, is of great help for achieving a correct diagnosis. As far as FISH analysis of the EWSR1 gene is concerned a major caveat is represented by the fact that its rearrangement can occur in a variety of unrelated lesions. As a consequence, any result needs to be mandatorily interpreted in context with morphology and immunohistochemical findings.
The identification of gene copy number variations has also proved extremely helpful. The perfect example is represented by dedifferentiated liposarcoma, a pleomorphic mostly (but not exclusively) retroperitoneal adipocytic malignancy that, in contrast with other sarcoma such as leiomyosarcoma, exhibits the tendency to recur locally with a comparatively lower rate of metastatic spread. As a consequence, the surgical treatment of retroperitoneal dedifferentiated liposarcoma is currently based on multivisceral resection aimed to prolong the time to local destructive recurrences. The recognition of dedifferentiated liposarcoma is generally based on the identification of a welldifferentiated lipogenic component associated with a high grade, most often non-lipogenic, sarcoma. In consideration of the increasing tendency to use core biopsies for diagnostic purposes, not infrequently the well-differentiated lipogenic component is not made available. In this context, the detection of MDM2 amplification by FISH or quantitative RT-PCR certainly represents a useful diagnostic adjunct [15] .
Supporting diagnosis in non-canonical clinical presentations As a result of the widespread use of molecular pathology as a confirmatory diagnostic tool, the range of clinical presentations of many entities has broadened. In fact, the combination of morphological criteria and genetics validates the recognition of rare diseases even when arising at non-canonical anatomic locations. This is particularly true for referral centers wherein challenging cases tend to concentrate. Molecular genetics has undoubtedly greatly contributed for instance to the identification of primary Ewing sarcoma of the skin, kidney, and meninges, as well of synovial sarcomas occurring at visceral sites such as the lungs and the gastrointestinal tract.
Distinguishing true sarcomas from benign mimics As already mentioned, the morphological appearance of mesenchymal lesions not always reflects the clinical behavior. The distinction of sarcomas from benign mimics most often relies on morphologic criteria; however, in a minority of cases molecular genetics may also prove diagnostically helpful. This is particularly true when dealing with lowgrade fibromyxoid sarcoma (LGFMS), a deceptively bland looking spindle cell mesenchymal malignancy characterized by an aggressive clinical behavior on long-term basis. The differential diagnosis of LGFMS includes benign lesions such as perineurioma, neurofibroma, cellular myxoma, and nodular fasciitis, as well locally aggressive neoplasms such as desmoid fibromatosis. Even if MUC4 expression is currently regarded as a key diagnostic feature, the identification of FUS rearrangement via interphase FISH or the identification of either FUS-CREB3L2 or FUS-CREB3L2 transcripts represents an extremely useful diagnostic tool [16] . As mentioned, desmoid fibromatosis enters the differential diagnosis and it should be, therefore, noted that in addition to immunohistochemical detection of nuclear accumulation of β-catenin, mutational analysis of the CTNNB1 gene may also represent a valuable diagnostic tool [17] .
Identification of molecular predictive and prognostic markers
During the last decade, several attempts have been made to determine the prognostic value of molecular genetic findings. Most analyses have focused on Ewing sarcoma, alveolar rhabdomyosarcoma and synovial sarcoma. Following initial enthusiasm, we have to admit that subsequent results have been contradicting and at this moment no meaningful molecular prognostic stratification can be foreseen. Also the attempt to correlate molecular status and clinical behavior in desmoid fibromatosis has proved controversial. A potential exception is represented by a recently published molecular signature named "CINSARC" that reportedly allows better separation of grade 2 sarcomas [18] . Nonetheless, this attempt was based on the use of a relatively complex technique (CGH-array) and requires availability of fresh material. Both factors may unfortunately hamper a large-scale clinical application of CINSARC.
An extremely important, clinically relevant exception is represented by gastrointestinal stromal tumors (GIST), wherein the type of mutations involving both the KIT and PDGFRA genes are associated with distinctive outcomes [19] . As examples, it is now well known that deletions occurring at the exon 11 of the KIT gene are associated with more aggressive disease, whereas mutations of exon 18 of the PDGFRA gene generally identify a more indolent clinical course. Again GIST represents the best example of successful prediction of response to treatment in sarcomas. Distinct mutation types reflect different objective response rates (greater for KIT exon 11 mutation and much lower for the so-called wild-type GIST) as well as different progression-free survival and overall survival. Also, the presence of specific mutations of the ex 18 of the PRGFRA gene (D842V) predicts primary resistance to tyrosine kinase inhibitors. Mutational analysis in GIST impacts also over dose selection: in fact the progression-free survival of GIST patients with KIT exon 9 mutations is known to be significantly better in patients treated with 800 mg of imatinib as compared to 400 mg per day.
It has also to be stressed how molecular pathology/genetics represents the most valuable tool in order to identify and validate new therapeutic targets. Good examples are represented by ALK in inflammatory myofibroblastic tumor [20] , MDM2 and CDK4 in dedifferentiated liposarcoma, the mTOR pathway in malignant PEComa and lymphangioleiomyomatosis, PDGFB in dermatofibrosarcoma protuberans [21] , KDR in angiosarcoma, NTRK3 in GIST [22] , and CSF1 in giant cell tumor of tendon sheath [23] .
The grading of soft tissue sarcomas
Soft tissue sarcomas tend to behave aggressively and metastasize in a large percentage of cases. Tumor size, location, depth, and histological type are all prognostic factors in terms of metastatic risk and overall survival.
With many exceptions, histologic typing does not provide sufficient information for predicting the clinical course of the disease and, therefore, grading systems based on histological parameters were introduced to provide a more accurate estimation of the degree of malignancy of tumors.
Several different grading systems have been developed. The most successful have been the three-tiered systems of the National Cancer Institute (NCI) and the French Federation of Cancer Centers Sarcoma Group (FNCLCC) scheme. The FNCLCC approach offers slightly better discrimination between low-and high-grade sarcomas, the intermediate group being smaller [24, 25] . The FNCLCC grading system is based on the evaluation of three main parameters: 1. Differentiation; 2. Mitotic count; 3. Presence of necrosis. As summarized in Table 9 , each parameter generates a score the sum of which determines a final score that assigns the tumor to one of the three groups.
Prognostic nomograms that recently have incorporated the revised WHO classification of soft tissue tumors represent an additional valuable clinical tool [26] . From one of these monograms, a freely downloadable application for portable devices termed "Sarculator" has been also generated.
In conclusion, soft tissue sarcomas represent a heterogeneous group of clinicopathologic distinct tumor entities. Correct classification is mandatory in order to ensure a proper therapeutic approach. Diagnosis is currently based on the integration of light microscopic morphology, immunohistochemistry and molecular genetics. Both immunohistochemistry and genetics have proved extremely valuable not only in increasing diagnostic accuracy, but also in refining classification and validating newly described tumor entity.
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